Hepatic Stellate Cells Promote Tumor Progression by Enhancement of Immunosuppressive Cells in an Orthotopic Liver Tumor Mouse Model

Overview

Journal Lab Invest

Specialty Pathology

Date 2013 Dec 4

PMID 24296878

Citations 57

Authors

Wenxiu Zhao

Lei Zhang

Yaping Xu

Zhengqi Zhang

Guangli Ren

Kai Tang

Penghao Kuang

Bixing Zhao

Zhenyu Yin

Xiaomin Wang

Affiliations

Soon will be listed here.

Abstract

The immunosuppressive properties of hepatic stellate cells (HSCs) contribute to the occurrence and development of hepatocellular carcinoma (HCC). The accumulation of cells with immune suppressive activities, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) is a key mechanism for tumor immune evasion. However, the impact of HSCs on immune cell populations in tumor-bearing hosts is unclear. In this study, we established an orthotopic liver tumor mouse model for studying the complex tumor-host interactions in HCC. The activated HSCs promoted HCC growth not only induced tumor angiogenesis and lymphangiogenesis, but also significantly increased the suppressive immune cell population of Tregs and MDSCs in the spleen, bone marrow, and tumor tissues of the tumor-bearing mice. Murine HCC cell line H22-activated HSCs also expanded the expression of Tregs and MDSCs in vitro. In conclusion, our study suggests a novel role for HSCs in the HCC microenvironment. HSCs can promote HCC progression by enhancement of the immunosuppressive cell population. Targeting HSCs, which is a new concept in adjuvant immunotherapy, may be introduced in the near future to improve the outcome of patients with HCC.

Citing Articles

Cross-Talk Between Tumor Cells and Stellate Cells Promotes Oncolytic VSV Activity in Intrahepatic Cholangiocarcinoma.

Neumeyer V, Chavan P, Steiger K, Ebert O, Altomonte J Cancers (Basel). 2025; 17(3).

PMID: 39941881 PMC: 11816849. DOI: 10.3390/cancers17030514.

Exosome-mediated Crosstalk in the Tumor Immune Microenvironment: Critical Drivers of Hepatocellular Carcinoma Progression.

Ge Y, Jiang L, Dong Q, Xu Y, Yam J, Zhong X J Clin Transl Hepatol. 2025; 13(2):143-161.

PMID: 39917466 PMC: 11797817. DOI: 10.14218/JCTH.2024.00302.

Locoregional therapies combined with immune checkpoint inhibitors for liver metastases.

Zhang X, Zhou Y, Wei G, Luo Y, Qiu M Cancer Cell Int. 2024; 24(1):302.

PMID: 39217341 PMC: 11365172. DOI: 10.1186/s12935-024-03484-1.

Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.

Du G, Dou C, Sun P, Wang S, Liu J, Ma L Front Immunol. 2024; 15:1431211.

PMID: 39136031 PMC: 11317284. DOI: 10.3389/fimmu.2024.1431211.

Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells.

Chen L, Ye X, Yang L, Zhao J, You J, Feng Y J Natl Cancer Cent. 2024; 4(1):25-35.

PMID: 39036388 PMC: 11256631. DOI: 10.1016/j.jncc.2024.01.002.

References

Jiang G, Yang H, Wang L, Wildey G, Fung J, Qian S . Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner. Transplantation. 2008; 86(11):1492-502. PMC: 2888269. DOI: 10.1097/TP.0b013e31818bfd13. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Ichikawa S, Mucida D, Tyznik A, Kronenberg M, Cheroutre H . Hepatic stellate cells function as regulatory bystanders. J Immunol. 2011; 186(10):5549-55. PMC: 3132534. DOI: 10.4049/jimmunol.1003917. View

Facciabene A, Motz G, Coukos G . T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012; 72(9):2162-71. PMC: 3342842. DOI: 10.1158/0008-5472.CAN-11-3687. View

Zhao W, Su W, Kuang P, Zhang L, Liu J, Yin Z . The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma. Int J Oncol. 2012; 41(2):457-64. PMC: 3582803. DOI: 10.3892/ijo.2012.1497. View

Chou H, Hsieh C, Yang H, Wang L, Arakawa Y, Brown K . Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology. 2011; 53(3):1007-19. PMC: 3079329. DOI: 10.1002/hep.24162. View

Hu C, Gan J, Zhang R, Cheng Y, Huang G . Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 2010; 46(2):156-64. DOI: 10.3109/00365521.2010.516450. View

Bianchi G, Borgonovo G, Pistoia V, Raffaghello L . Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Histol Histopathol. 2011; 26(7):941-51. DOI: 10.14670/HH-26.941. View

Unitt E, Rushbrook S, Marshall A, Davies S, Gibbs P, Morris L . Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005; 41(4):722-30. DOI: 10.1002/hep.20644. View

10.

Ostrand-Rosenberg S, Sinha P . Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182(8):4499-506. PMC: 2810498. DOI: 10.4049/jimmunol.0802740. View

11.

Budhu A, Forgues M, Ye Q, Jia H, He P, Zanetti K . Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10(2):99-111. DOI: 10.1016/j.ccr.2006.06.016. View

12.

Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H . Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009; 50(3):799-807. PMC: 6357774. DOI: 10.1002/hep.23054. View

13.

Gehad A, Lichtman M, Schmults C, Teague J, Calarese A, Jiang Y . Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. J Invest Dermatol. 2012; 132(11):2642-51. PMC: 3449043. DOI: 10.1038/jid.2012.190. View

14.

Hoechst B, Ormandy L, Ballmaier M, Lehner F, Kruger C, Manns M . A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008; 135(1):234-43. DOI: 10.1053/j.gastro.2008.03.020. View

15.

Yu M, Chen C, Liang X, Wang L, Gandhi C, Fung J . Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology. 2004; 40(6):1312-21. DOI: 10.1002/hep.20488. View

16.

Ye X, Yu S, Bian X . Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics. 2010; 37(7):423-30. DOI: 10.1016/S1673-8527(09)60061-8. View

17.

Filipazzi P, Huber V, Rivoltini L . Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2011; 61(2):255-263. PMC: 11029611. DOI: 10.1007/s00262-011-1161-9. View

18.

Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z . CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007; 252(1):86-92. DOI: 10.1016/j.canlet.2006.12.012. View

19.

Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C . Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer. 2011; 129(11):2651-61. DOI: 10.1002/ijc.25920. View

20.

Ilkovitch D, Lopez D . The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 2009; 69(13):5514-21. PMC: 2706931. DOI: 10.1158/0008-5472.CAN-08-4625. View